Richard J Craig

US Patent:

6632961, Oct 14, 2003

Filed:

May 21, 1999

Appl. No.:

09/316856

Inventors:

Megumi Kawai - Libertyville IL
Jack Henkin - Highland Park IL
George S. Sheppard - Wilmette IL
Richard A. Craig - Racine WI

Assignee:

Abbott Laboratories - Abbott Park IL

International Classification:

C07K 6500

US Classification:

562405, 514 19, 562553, 562562

Abstract:

Compounds having Formula I or pharmaceutically acceptable salts or prodrugs thereof, are useful for treating pathological states which arise from or are exacerbated by angiogenesis. The invention also relates to pharmaceutical compositions comprising these compounds and to methods of inhibiting angiogenesis in a mammal.

US Patent:

6849757, Feb 1, 2005

Filed:

Jul 10, 2003

Appl. No.:

10/616628

Inventors:

Megumi Kawai - Libertyville IL, US
Jack Henkin - Highland Park IL, US
George S. Sheppard - Wilmette IL, US
Richard A. Craig - Racine WI, US

Assignee:

Abbott Laboratories - Abbott Park IL

International Classification:

C07C 6976

US Classification:

560102, 560 41, 562492, 564169

Abstract:

Compounds having Formula I or pharmaceutically acceptable salts or prodrugs thereof, are useful for treating pathological states which arise from or are exacerbated by angiogenesis. The invention also relates to pharmaceutical compositions comprising these compounds and to methods of inhibiting angiogenesis in a mammal.

US Patent:

7030262, Apr 18, 2006

Filed:

Aug 6, 2003

Appl. No.:

10/635342

Inventors:

Nwe Y. BaMaung - Niles IL, US
Richard A. Craig - Racine WI, US
Jack Henkin - Highland Park IL, US
Megumi Kawai - Libertyville IL, US
Xenia B. Searle - Grayslake IL, US
George S. Sheppard - Wilmette IL, US
Jieyi Wang - Lake Bluff IL, US

Assignee:

Abbott Laboratories - Abbott Park IL

International Classification:

C07C 331/00

US Classification:

560 19, 560155, 562433, 562553

Abstract:

Compounds having the formula are useful for treating conditions which arise from or are exacerbated by angiogenesis. Also disclosed are pharmaceutical compositions comprising the compounds, methods of treatment using the compounds, methods of inhibiting angiogenesis, and methods of treating cancer.

US Patent:

20020091148, Jul 11, 2002

Filed:

Sep 14, 2001

Appl. No.:

09/952603

Inventors:

Nwe BaMaung - Niles IL, US
Richard Craig - Racine WI, US
Megumi Kawai - Libertyville IL, US
Jieyi Wang - Lake Bluff IL, US
Yujia Dai - Gurnee IL, US
Yan Guo - Gurnee IL, US
George Sheppard - Wilmette IL, US
Mary Verzal - Kenosha WI, US
Anil Vasudevan - Gurnee IL, US
Michael Michaelides - Libertyville IL, US

International Classification:

A61K031/404

US Classification:

514/414000, 514/419000

Abstract:

3-Substituted indole carbohydrazides having the formula are useful for inhibiting angiogenesis and cell proliferation. Also disclosed are compositions which inhibit angiogenesis and cell proliferation and methods of inhibiting angiogenesis and cancer in a mammal.

US Patent:

57565317, May 26, 1998

Filed:

Apr 30, 1996

Appl. No.:

8/640271

Inventors:

Clint D. W. Brooks - Libertyville IL
Richard A. Craig - Racine WI
David E. Gunn - Hamden CT
Jimmie L. Moore - Gurnee IL
Andrew O. Stewart - Libertyville IL

Assignee:

Abbott Laboratories - Abbott Park IL

International Classification:

C07D20912
C07D20914
A61K 3140
A61K 31405

US Classification:

514408

Abstract:

The present invention provides a class of substituted indole and indene iminoxy derivatives of the formula ##STR1## which inhibit leukotriene biosynthesis and are useful in the treatment of allergic and inflammatory disease states.

US Patent:

55062610, Apr 9, 1996

Filed:

May 9, 1994

Appl. No.:

8/239648

Inventors:

Dee W. Brooks - Libertyville IL
Andrew O. Stewart - Libertyville IL
Richard A. Craig - Racine WI

Assignee:

Abbott Laboratories - Abbott Park IL

International Classification:

C07D33332
C07D33334
A61K 3138
A61K 31385

US Classification:

514438

Abstract:

Compounds of the structure ##STR1## wherein Z is selected from optionally substituted thienyl, thiazolyl, oxazolyl and furyl are potent inhibitors of lipoxygenase enzymes and thus inhibit the biosynthesis of leukotrienes. These compounds are useful in the treatment or amelioration of allergic and inflammatory disease states.

US Patent:

56165960, Apr 1, 1997

Filed:

Apr 13, 1995

Appl. No.:

8/416807

Inventors:

Anwer Basha - Lake Forest IL
Clint D. W. Brooks - Libertyville IL
Pramila Bhatia - Libertyville IL
Richard A. Craig - Racine WI
James D. Ratajczyk - Waukegan IL
Andrew O. Stewart - Libertyville IL

Assignee:

Abbott Laboratories - Abbott Park IL

International Classification:

A61K 3142
A61K 31425
C07D26330
C07D27720

US Classification:

514365

Abstract:

The invention relates to compounds having activity to inhibit lipoxygenase enzyme activity, to pharmaceutical compositions comprising these compounds, and to a medical method of treating. More particularly, this invention concerns certain substituted arylalkynyl- and ((heteroaryl)alkynyl)-N-hydroxy-ureas which inhibit leukotriene biosynthesis, to pharmaceutical compositions of these compounds and to a method of inhibiting leukotriene biosynthesis.

US Patent:

58639462, Jan 26, 1999

Filed:

Jun 6, 1996

Appl. No.:

8/660046

Inventors:

Clint D. W. Brooks - Libertyville IL
Richard A. Craig - Racine WI
Teodozyj Kolasa - Lake Villa IL
Andrew O. Stewart - Libertyville IL

Assignee:

Abbott Laboratories - Abbott Park IL

International Classification:

A61K 31195
C07C25158

US Classification:

514564

Abstract:

Compounds having the formula ##STR1## or a pharmaceutically acceptable salt thereof wherein Y is selected from halogen, alkyl, and haloalkyl; n is 0, 1, 2, or 3; X is absent or is alkylene; A is absent or is selected from optionally substituted alkylene, optionally substituted cycloalkylene, optionally substituted cycloalkylene wherein one or two of the carbon atoms is replaced with one or two heteroatoms independently selected from O, S, and N, optionally substituted alkenylene, and ##STR2## or R. sup. 2 and A together define a saturated 5- to 8-membered optionally substituted carbocyclic or heterocyclic ring to which the group Z is attached; Z is selected from (a) hydrogen, (b) COM wherein M is selected from the group consisting of --OR. sup. 5, a pharmaceutically acceptable cation, --NR. sup. 7 R. sup. 8, and a pharmaceutically acceptable, metabolically cleavable group, (c) --OR. sup.